In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.
Multiple myeloma has been considered a weakly immunogenic malignancy that can cause profound defects in the immune system. An important issue for the immunotherapy of myeloma is the identification of appropriate tumor-associated antigens (TAAs). Recently, hTERT (human telomerase reverse transcriptase) was detected on a majority of human malignancies. In the studies reported here, we studied antigen-specific and HLA-A2-restricted cytotoxic activity against an ARH77 myeloma cell line in vitro. An HLA-A2-specific hTERT-derived nonapeptide ((540)ILAKFLHWL(548)) was used as a TAA. Myeloma-specific cytotoxic activity of hTERT-reactive cytotoxic lymphocytes (CTLs) was established by repeated stimulation of the CTLs via dendritic cells loaded with hTERT-derived nonapeptide. These studies were able to demonstrate that hTERT-reactive T-lymphocytes can be identified and expanded using relatively simple in vitro techniques consisting of antigen-specific stimulation, immunomagnetic sorting, and then induction of rapid expansion.
Kryukov
Fedor
F
University Cell Immunotherapy Center, Masaryk University, Brno, Czech Republic. f.kyukov@gmail.com
Ocadlíková
Darina
D
Kovárová
Lucie
L
Buresová
Ivana
I
Hájek
Roman
R
Michálek
Jaroslav
J
D000951:Antigens, Neoplasm / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D009101:Multiple Myeloma / Q000276:immunology*; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019098:Telomerase / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D014161:Transduction, Genetic; D014162:Transfection
D000951:Antigens, Neoplasm; D010446:Peptide Fragments; C437311:telomerase reverse transcriptase (540-548); C509186:TERT protein, human; D019098:Telomerase